Cynosure Lutronic, a global medical aesthetics company headquartered in the United States, showcased its core portfolio and engaged in academic exchange at the 45th Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS 2026). For overseas buyers and distributors, this signals strong clinical validation and growing market traction for the company's key devices, particularly the dual-monopolar RF system XERF, which is gaining momentum in the aesthetics supply chain.
Conference and abstract highlights
ASLMS 2026, held in Savannah, Georgia, USA, is a leading international conference for laser and energy-based medical devices, gathering dermatologists, plastic surgeons, researchers, and industry professionals. Cynosure Lutronic had 29 research abstracts accepted for the event, with 10 specifically focused on the XERF dual-monopolar radiofrequency device. This high number of XERF-related studies underscores the device's rising profile in the global aesthetics market.
XERF research scope and plenary session
Accepted XERF studies covered a broad range of topics, including tissue response analysis using dual frequencies of 6.78 MHz and 2 MHz, energy delivery characteristics based on depth selectivity, and evaluation of direct and peripheral effects using 3D human skin models. Notably, XERF was featured in the Plenary Session, a platform for cutting-edge medical technologies. Dr. Jordan Wang and Dr. Jeffrey Esslinger served as session speakers, sharing clinical experiences and trends in RF-based procedures centered on XERF.
Other portfolio studies and learning lab
Beyond XERF, Cynosure Lutronic presented clinical research on its flagship products: the 755 nm Alexandrite laser PicoSure Pro, the non-invasive fractional laser MOSAIC 3D, and the Nd:YAG laser DermaV. Studies covered both standalone and combination treatments. The company also operated a dedicated Cynosure Lutronic Learning Lab at the conference, where attendees could experience devices like XERF, DermaV, and eCO2 3D, and discuss treatment protocols and clinical applications.
What buyers should watch
For importers and distributors, the strong academic backing for XERF and the broader portfolio at ASLMS 2026 indicates robust clinical evidence supporting these devices. The dual-monopolar RF technology, with its dual-frequency capability, may offer differentiated treatment options in the competitive RF aesthetics market. Buyers should monitor how these research findings translate into market demand and regulatory approvals in their regions.
Source: Read the original report | Published: June 08, 2026